AR124916A2 - Piridinas sustituidas con heteroarilo y métodos de uso - Google Patents

Piridinas sustituidas con heteroarilo y métodos de uso

Info

Publication number
AR124916A2
AR124916A2 ARP220100344A ARP220100344A AR124916A2 AR 124916 A2 AR124916 A2 AR 124916A2 AR P220100344 A ARP220100344 A AR P220100344A AR P220100344 A ARP220100344 A AR P220100344A AR 124916 A2 AR124916 A2 AR 124916A2
Authority
AR
Argentina
Prior art keywords
methods
heteroaryl
substituted pyridines
cystic fibrosis
compounds
Prior art date
Application number
ARP220100344A
Other languages
English (en)
Inventor
Der Plas Steven Emiel Van
Philip R Kym
Hans Kelgtermans
Stephen N Greszler
Marlon D Cowart
Ghjuvanni Petru Diunisu Coti
Andrew Bogdan
Robert J Altenbach
Xueqing Wang
Original Assignee
Abbvie Sarl
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl, Galapagos Nv filed Critical Abbvie Sarl
Publication of AR124916A2 publication Critical patent/AR124916A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención describe compuestos de fórmula (1), donde X¹, X², R¹, y R² son como se definen en la presente. La presente invención se relaciona con compuestos y su uso en el tratamiento de fibrosis quística, métodos para su producción, composiciones farmacéuticas que los comprenden, y métodos para tratar fibrosis quística mediante la administración de un compuesto de la invención.
ARP220100344A 2016-06-03 2022-02-18 Piridinas sustituidas con heteroarilo y métodos de uso AR124916A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
AR124916A2 true AR124916A2 (es) 2023-05-17

Family

ID=59014678

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170101516A AR108672A1 (es) 2016-06-03 2017-06-02 Piridinas sustituidas con heteroarilo y métodos de uso
ARP220100344A AR124916A2 (es) 2016-06-03 2022-02-18 Piridinas sustituidas con heteroarilo y métodos de uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP170101516A AR108672A1 (es) 2016-06-03 2017-06-02 Piridinas sustituidas con heteroarilo y métodos de uso

Country Status (34)

Country Link
US (2) US10138227B2 (es)
EP (1) EP3464282B1 (es)
JP (3) JP6968094B2 (es)
KR (1) KR102469995B1 (es)
CN (2) CN114671864A (es)
AR (2) AR108672A1 (es)
AU (3) AU2017273215B2 (es)
BR (1) BR112018074815A2 (es)
CA (1) CA3022216A1 (es)
CL (1) CL2018003323A1 (es)
CO (1) CO2018012171A2 (es)
CR (1) CR20180547A (es)
CY (1) CY1124031T1 (es)
DK (1) DK3464282T3 (es)
DO (1) DOP2018000257A (es)
EC (1) ECSP18094790A (es)
ES (1) ES2806873T3 (es)
HR (1) HRP20201068T1 (es)
HU (1) HUE050248T2 (es)
IL (3) IL303196A (es)
LT (1) LT3464282T (es)
MX (2) MX2018014758A (es)
PE (1) PE20190511A1 (es)
PH (1) PH12018502534B1 (es)
PL (1) PL3464282T3 (es)
PT (1) PT3464282T (es)
RS (1) RS60574B1 (es)
RU (2) RU2021127810A (es)
SG (1) SG11201808842VA (es)
SI (1) SI3464282T1 (es)
TW (3) TWI849782B (es)
UY (1) UY37272A (es)
WO (1) WO2017208115A1 (es)
ZA (1) ZA201808423B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
US10793547B2 (en) 2016-12-09 2020-10-06 Vertex Pharmaceuticals Incorporated Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
PT3752510T (pt) 2018-02-15 2023-03-15 Vertex Pharma Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) * 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
BR112022002605A2 (pt) 2019-08-14 2022-05-03 Vertex Pharma Formas cristalinas de moduladores de cftr
BR112022009185A2 (pt) * 2019-11-12 2022-07-26 Genzyme Corp Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
IL309501A (en) 2021-08-19 2024-02-01 Syngenta Crop Protection Ag Method for controlling pests resistant to diamide and compounds therefor
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414037B2 (en) * 2004-03-30 2008-08-19 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
ES2548292T3 (es) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
JP5645835B2 (ja) 2008-10-23 2014-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態
EA018891B1 (ru) * 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
ES2553771T3 (es) 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
CN103946221B (zh) * 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) * 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
AU2014264936B2 (en) 2013-05-07 2018-09-27 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
RU2708690C2 (ru) 2013-08-08 2019-12-11 Галапагос Нв Производные тиено[2,3-c]пиранов в качестве cftr модуляторов
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
PL3212189T3 (pl) 2014-10-31 2021-03-08 AbbVie Overseas S.à r.l. Podstawione chromany i sposób użycia
CA2981495C (en) * 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10047051B2 (en) 2015-06-02 2018-08-14 Abbvie S.Á.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CA3001094A1 (en) 2015-10-09 2017-04-13 Abbvie S.A.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
US9890158B2 (en) 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
BR112018072047A2 (pt) 2016-04-26 2019-02-12 AbbVie S.à.r.l. moduladores da proteína reguladora de condutância transmembranar de fibrose cística
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Also Published As

Publication number Publication date
EP3464282A1 (en) 2019-04-10
JP2019517455A (ja) 2019-06-24
RU2021127810A (ru) 2021-10-25
MX2021009322A (es) 2021-09-08
EP3464282B1 (en) 2020-04-22
US20190055229A1 (en) 2019-02-21
AR108672A1 (es) 2018-09-12
UY37272A (es) 2018-01-02
ES2806873T3 (es) 2021-02-18
IL262415A (en) 2018-12-31
IL288243B2 (en) 2023-11-01
LT3464282T (lt) 2020-09-10
KR20190015215A (ko) 2019-02-13
WO2017208115A1 (en) 2017-12-07
CN114671864A (zh) 2022-06-28
US10604515B2 (en) 2020-03-31
US20170349576A1 (en) 2017-12-07
KR102469995B1 (ko) 2022-11-24
CA3022216A1 (en) 2017-12-07
JP6968094B2 (ja) 2021-11-17
RS60574B1 (sr) 2020-08-31
IL288243B1 (en) 2023-07-01
PE20190511A1 (es) 2019-04-10
PT3464282T (pt) 2020-07-17
CN109311864B (zh) 2022-05-10
TW201802085A (zh) 2018-01-16
TWI797926B (zh) 2023-04-01
CN109311864A (zh) 2019-02-05
AU2017273215B2 (en) 2021-09-09
JP2022009448A (ja) 2022-01-14
AU2017273215A1 (en) 2018-10-25
HRP20201068T1 (hr) 2020-11-13
US10138227B2 (en) 2018-11-27
RU2018138707A (ru) 2020-07-14
AU2024202468A1 (en) 2024-05-02
AU2021282409A1 (en) 2021-12-23
TWI752961B (zh) 2022-01-21
SG11201808842VA (en) 2018-11-29
DOP2018000257A (es) 2018-12-31
PH12018502534A1 (en) 2019-10-21
IL262415B (en) 2021-12-01
RU2018138707A3 (es) 2020-08-24
ECSP18094790A (es) 2019-01-31
RU2756743C2 (ru) 2021-10-05
CR20180547A (es) 2019-10-30
KR20220162806A (ko) 2022-12-08
ZA201808423B (en) 2019-08-28
PL3464282T3 (pl) 2020-12-14
TW202329959A (zh) 2023-08-01
CY1124031T1 (el) 2022-03-24
BR112018074815A2 (pt) 2019-03-19
MX2018014758A (es) 2019-04-29
SI3464282T1 (sl) 2020-12-31
JP2023172889A (ja) 2023-12-06
HUE050248T2 (hu) 2020-12-28
JP7392211B2 (ja) 2023-12-06
DK3464282T3 (da) 2020-07-27
IL303196A (en) 2023-07-01
CO2018012171A2 (es) 2018-11-30
PH12018502534B1 (en) 2019-10-21
TW202214614A (zh) 2022-04-16
CL2018003323A1 (es) 2019-03-22
TWI849782B (zh) 2024-07-21
AU2021282409B2 (en) 2024-01-18
IL288243A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
AR124916A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
CO2017012566A2 (es) Piridinas sustituidas y método de uso
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2020004249A2 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CR20180374A (es) Compuestos heterocíclicos como inmunomoduladores
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции